Largest Pregnancy Study on Ocrelizumab: Insights from 5,095 Cases
New data from the largest pregnancy registry to date—tracking 5,095 pregnancies exposed to ocrelizumab (a CD20-directed monoclonal antibody) and natalizumab (an integrin inhibitor)—reveals these high-efficacy multiple sclerosis (MS) medications carry ... Read More